BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas

Détails bibliographiques
Auteurs principaux:	Nyman, H, Jerkeman, M, Karjalainen-Lindsberg, M, Banham, A, Enblad, G, Leppa, S
Format:	Conference item
Publié:	2008

Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas. par Nyman, H, Jerkeman, M, Karjalainen-Lindsberg, M, Banham, A, Enblad, G, Leppä, S

Publié 2009

Journal article